Nicole Massie, MD
Urogynecology and Reconstructive Pelvic Surgery · Homewood, ALNPI 1033182241
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,540 of the $8,004 with a category attached, or 69.2%. 25 manufacturers reported payments, led by Axonics, Inc. at 46.2% of the total. Reporting peaked in 2023 at $3,300 and has fallen 82.7% since, to $571 in 2025.
Across 265 payments — averaging $30.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$4K
- AbbVie$2K
- Sumitomo Pharma America, Inc.$481
- Astellas Pharma US Inc$399
- Medtronic$381
- Caldera Medical, Inc$370
- plus $1K from 19 others
What the payments were for
- Speaking & faculty fees$2733%
- Travel & lodging$1,80123%
- Food & beverage$5,54069%
- Education$3905%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 39 | $3,697 |
| AbbVie(2 entities) | 86 | $1,565 |
| Sumitomo Pharma America, Inc. | 33 | $481 |
| Astellas Pharma US Inc | 24 | $399 |
| Medtronic(2 entities) | 16 | $381 |
| Caldera Medical, Inc | 4 | $370 |
| Coloplast | 15 | $281 |
| Rochester Medical Corporation | 6 | $142 |
| Urovant Sciences Inc | 8 | $126 |
| Therapeuticsmd, Inc. | 9 | $122 |
| Boston Scientific | 4 | $76 |
| Pfizer | 4 | $61 |
| Procept Biorobotics Corporation | 1 | $50 |
| 180 Medical, Inc. | 2 | $38 |
| Antares Pharma, Inc. | 2 | $35 |
| Endo Pharmaceuticals Inc. | 2 | $28 |
| Conmed Corporation | 2 | $25 |
| Endo USA, Inc. | 1 | $24 |
| Convatec Inc. | 1 | $21 |
| Blue Earth Diagnostics | 1 | $20 |
| Dendreon Pharmaceuticals LLC | 1 | $18 |
| Abbott | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Duchesnay USA Incorporated | 1 | $12 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few urogynecology and reconstructive pelvic surgery providers in Alabamato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 554 | $392,302 |
| MyrbetriqMirabegron | 400 | $296,182 |
| Estradiol | 606 | $43,141 |
| NitrofurantoinNitrofurantoin Macrocrystal | 483 | $13,689 |
| Trospium Chloride ErTrospium Chloride | 50 | $13,386 |
| Tolterodine Tartrate ErTolterodine Tartrate | 43 | $7,989 |
| Trimethoprim | 153 | $7,438 |
| Mirabegron ErMirabegron | 15 | $7,216 |
| Solifenacin Succinate | 126 | $7,077 |
| Methenamine Hippurate | 82 | $4,447 |
| ImvexxyEstradiol | 12 | $2,407 |
| Oxybutynin Chloride ErOxybutynin Chloride | 115 | $2,013 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 173 | $1,513 |
| Trospium Chloride | 26 | $1,161 |
| Cephalexin | 75 | $906 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $481 | $392,302554 claims |
| Astellas Pharma US IncMyrbetriq | $399 | $296,182400 claims |
| Therapeuticsmd, Inc.Imvexxy | $122 | $2,40712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in Alabamaon file to place this against a meaningful peer group, so we don't.
Other urogynecology and reconstructive pelvic surgery in Homewood
- Alison PickeringHomewood$11K
- Meagan CramerHomewood$3K
- Brent ParnellBirmingham$208K
- Charles HanesMobile$28K
- Himanshu AggarwalMontgomery$19K
- George FahyBay Minette$14K
- Vincent ScottMobile$10K
- David EllingtonBirmingham$9K
- Robert BrownMobile$8K
- Gabriela HalderBirmingham$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.